Clinical Trial

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Study acronym: TAYLOR
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-24; most recent amendment 2025-08-11.
Trial Details
NCT Number NCT05888857
Lead Sponsor Institut Bergonié
Collaborators: National Cancer Institute, France, AstraZeneca
Conditions Advanced Solid Tumor
Enrollment 102 participants
Start Date 2025-09
Primary Completion 2026-03 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-13